共 50 条
- [1] Real world comparison of major bleeding risk among nonvalvular atrial fibrillation patients newly initiated on apixaban, warfarin, dabigatran or rivaroxaban: a 1:1 propensity-score matched analysis[J]. PHARMACOTHERAPY, 2016, 36 (12): : E213 - E213Lip, GregoryKeshishian, AllisonKamble, ShitalPan, XianyingBurns, LeahMardekian, JackMasseria, CristinaBruno, AmandaPhatak, Hemant
- [2] Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin A propensity score matched analysis[J]. THROMBOSIS AND HAEMOSTASIS, 2016, 116 (05) : 975 - 986Lip, Gregory Y. H.Keshishian, AllisonKamble, ShitalPan, XianyingMardekian, JackHorblyuk, RuslanHamilton, Melissa
- [3] Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin[J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1085 - 1085Lip, G. Y. H.Pan, X.Kamble, S.Kawabata, H.Mardekian, J.Masseria, C.Bruno, A.Phatak, H.
- [4] BLEEDING RISK AMONG JAPANESE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATED ON APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN IN THE REAL WORLD[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 443 - 443Wang, FengMurata, TatsunoriIzumi, NaokoKida, MakotoHorblyuk, RuslanTerayama, Yasuo
- [5] Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (09) : 752 - 763Lip, Gregory Y. H.Pan, XianyingKamble, ShitalKawabata, HughMardekian, JackMasseria, CristinaBruno, AmandaPhatak, Hemant
- [6] REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 668 - 668Amin, AlpeshKeshishian, AllisonXie, LinBaser, OnurPrice, KwanzaVo, LienMardekian, JackMendoza, MarioSinghal, ShalabhPatel, ChadOdell, KevinTrocio, Jeffrey
- [7] Is major bleeding risk for oral anticoagulants similar between non-valvular atrial fibrillation patients newly initiated on warfarin and propensity-score matched NOAC initiators? A real world study[J]. EUROPEAN HEART JOURNAL, 2016, 37 : 493 - 493Lip, G. Y. H.Keshishian, A.Kamble, S.Pan, X.Burns, L.Mardekian, J.Horbkyuk, R.Hamilton, M.
- [8] Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population[J]. EUROPEAN HEART JOURNAL, 2017, 38 : 964 - 964Amin, A.Keshishian, A.Trocio, J.Dina, O.Le, H.Rosenblatt, L.Mardekian, J.Zhang, Q.Baser, O.Liu, X.Vo, L.
- [9] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban[J]. PLOS ONE, 2018, 13 (11):Tepper, Ping G.Mardekian, JackMasseria, CristinaPhatak, HemantKamble, ShitalAbdulsattar, YounosPetkun, WilliamLip, Gregory Y. H.
- [10] Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records[J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084Lin, I.Masseria, C.Mardekian, J.Frean, M.Phatak, H.Kamble, S.Abdulsattar, Y.Petkun, W.Menzin, J.Lip, G. Y. H.